其 他 安 全 警 示
|
| |
| FDA releases information Natalizumab (marketed as Tysabri) (English Only) |
| |
The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. At this time, the FDA is not requiring changes regarding PML to the Tysabri prescribing information or to the Tysabri risk management plan. The relevant link for the news is:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm182667.htm
Situation in Hong Kong: The above product is not registered in Hong Kong.
Ends/Friday, September 18, 2009
Issued at HKT 18:00
|
| |
|
